Topics

FDA Grants Durvalumab Orphan Drug Status in Small Cell Lung Cancer

11:41 EDT 12 Jul 2019 | OncLive

The FDA has granted an Orphan Drug Designation to durvalumab for the treatment of patients with small cell lung cancer, according to AstraZeneca, the developer of the PD-L1 inhibitor.

Original Article: FDA Grants Durvalumab Orphan Drug Status in Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Durvalumab Orphan Drug Status in Small Cell Lung Cancer"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...